Aggressive follicular lymphoma disease overview

- Aggressive FL is aggressively behaving FL, is associated with poor outcomes.
- Early progression from FL to high-grade lymphoma is defined as progression-free survival (PFS) less than 2 years.
- Early progression is defined as progression of disease within 24 months of frontline treatment.
- Exclusion criteria: patients with prior CD19 CAR T cell therapy.

Patient case presentation

- Patient demographics:
  - Age: 66
  - Sex: Male
  - Ethnicity: Not Hispanic or Latino

- Clinical history:
  - Male, 66 years old, Asian
  - Weight: 82.4 kg
  - Height: 180 cm
  - BMI: 25.4
  - SGA: 2

- Medical history and disease characteristics:
  - Prior treatments:
    - Rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP)
    - Rituximab and idelalisib

- Treatment:
  - Developed at Caribou Biosciences, Inc., Berkeley, CA.
  - T cell receptor alpha T cells; (N=6, completed)

Patient efficacy: CR ongoing through month 15

Discussion

- CR demonstrated promising safety and efficacy in r/r B cell lymphoma.
- CB-010: 100% CR rate (6/6) was observed as best response by the investigator and independent radiologist assessment. At 6 months, 3/6 patients remained in CR.
- This patient remains on trial in CR with a duration of response through Month 24.
- AE related reactions: hypokalemia, sinusitis, rhinitis, sepsis.
- GvHD, CRS, or ICANS observed.

8 systemic anti-cancer lines of therapy prior to CB-010

<table>
<thead>
<tr>
<th>Year</th>
<th>Therapy A</th>
<th>Therapy B</th>
<th>Therapy C</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>Rituximab</td>
<td>Rituximab</td>
<td>Rituximab</td>
</tr>
<tr>
<td>2014</td>
<td>Idelalisib</td>
<td>Idelalisib</td>
<td>Idelalisib</td>
</tr>
<tr>
<td>2015</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
</tr>
<tr>
<td>2016</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
</tr>
<tr>
<td>2017</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
</tr>
<tr>
<td>2018</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
</tr>
<tr>
<td>2019</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
</tr>
<tr>
<td>2020</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
<td>Ofatumumab</td>
</tr>
</tbody>
</table>

CB-010: ANTLER trial

- CB-010: a novel, one-time administration of r/r B cell lymphoma.
- CB-010: designed to improve persistence of antitumor activity.
- CB-010: has PD-1 KO designed to improve persistence of antitumor activity.
- CB-010: a phase 1 trial designed to assess the safety, tolerability, and efficacy of CB-010.
- CB-010: ongoing at the next dose level of Dose level 2, 4 microglobulin, FLIPI: Follicular Lymphoma International Prognostic Index, OS: overall survival.